Noble Trims PT on TherapeuticsMD (TXMD) to $17.50 Following Q4 Results; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:02 PM ESTCompany to Present additional positive phase 3 data for TX-004HR at the ISSWSH annual meeting
Management to host conference call today at 4:30 p.m. EST
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its fourth quarter and full year financial results for 2015.
2015 and Recent Developments
Net revenue for the companys prescription prenatal vitamin business increased to approximately $20.1 million in 2015 compared with approximately $15.0 million for the prior year. Net... More